Neuronascent
Pharmaceuticals, 6030 Daybreak Cir, Clarksville, Maryland, 21029, United States, 1-10 Employees
Phone Number: 41********
Who is NEURONASCENT
Neuronascent (NNI) is a small corporation, that we believe has an over-sized opportunity to improve the well-being of millions of patients suffering from chronic neurodegenerative disorde...
Read More
- Headquarters: 6030 Daybreak Cir, Clarksville, Maryland, 21029, United States
- Date Founded: 2004
- Employees: 1-10
- Revenue: Under $1 Million
- Active Tech Stack: See technologies
- CEO: Judith Kelleher-Andersson
Industry: Pharmaceuticals
SIC Code: 2834 | NAICS Code: 325412 | Show More
Does something look wrong? Fix it. | View contact records from NEURONASCENT
Neuronascent Org Chart and Mapping
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Neuronascent
Answer: Neuronascent's headquarters are located at 6030 Daybreak Cir, Clarksville, Maryland, 21029, United States
Answer: Neuronascent's phone number is 41********
Answer: Neuronascent's official website is https://neuronascent.com
Answer: Neuronascent's revenue is Under $1 Million
Answer: Neuronascent's SIC: 2834
Answer: Neuronascent's NAICS: 325412
Answer: Neuronascent has 1-10 employees
Answer: Neuronascent is in Pharmaceuticals
Answer: Neuronascent contact info: Phone number: 41******** Website: https://neuronascent.com
Answer: Neuronascent (NNI) is a small corporation, that we believe has an over-sized opportunity to improve the well-being of millions of patients suffering from chronic neurodegenerative disorders that lack any disease-modifying therapeutic options. As we move toward this goal, we have built a strong track record of meeting critical drug-development milestones, which is of importance to investors and future pharmaceutical partners. Using a novel screening process developed by Neuronascent, the Company was able to identify small molecule therapeutics that generated new neurons in the brain and ensured that these new neurons survived to functionality under neurodegenerative conditions. These small molecule candidates proved successful not only on human neuronal progenitors in a lab dish, but showed the same capacity in animal models of chronic neurological diseases. NNI's synthetic therapeutic candidates are optimized and patented. These orally available candidates have been found to be safe in all testing to date. Our lead candidate for Alzheimers and potentially for Parkinsons disease, has completed in first-in-human testing (Phase 1a), with no significate safety concerns for this therapeutic in healthy aged subjects. The Company is based in Clarksville, Maryland, United States.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Sign in to CIENCE GO Data to uncover contact details
Free credits every month